Exelixis, Inc.
WHO'M
ai
Digital Profiler. Simply click the AI button
FIGI: BBG000BQ4WF8
EXEL
Exelixis, Inc.
GICS: -
·
Sector: Healthcare
·
Sub-Sector: Biotechnology
NAME
Exelixis, Inc.
ISIN
US30161Q1040
TICKER
EXEL
MIC
XNAS
REUTERS
EXEL.OQ
BLOOMBERG
EXEL US
Financial Intelligence
FOR INVESTORS
FOR TRADERS
Securities Trading
Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Mon, 06.01.2025
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 5:15 p.m. PT / 8:15 p.m. PT.
To access the webcast link, log onto www.exelixis.com and proceed t...
Exelixis
Wed, 27.11.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in December:
Piper Sandler 36th Annual Healthcare Conference: Exelixis is scheduled to present at 8:30 a.m. ET / 5:30 a.m. PT on Tuesday, December 3 in New York City.
Citi 2024 Global Healthcare Confe...
Exelixis
Tue, 26.11.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (CABOMETYX®) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will b...
Exelixis
Thu, 07.11.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:
Guggenheim’s Inaugural Healthcare Innovation Conference: Exelixis is scheduled to present at 9:00 a.m. ET / 6:00 a.m. PT on Tuesday, November 12 in Boston.
Stifel 2024 Healthcare Conference...
Exelixis
Tue, 29.10.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the third quarter of 2024, provided an update on progress toward achieving key corporate objectives, and detailed its recent and anticipated commercial, clinical and pipeline development milestones.
“The favorable ruling on our cabozantinib intellectual property estate and recentl...
Exelixis
Tue, 15.10.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) announced today that its third quarter 2024 financial results will be released on Tuesday, October 29, 2024 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available...
Exelixis
Tue, 15.10.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced that in the lawsuit Exelixis, Inc. (Exelixis) vs. MSN Laboratories Private Limited et al. (MSN), Civil Action No. 22-00228 (Consolidated), the U.S. District Court for the District of Delaware ruled in Exelixis’ favor, rejecting MSN’s challenge to three Orange Book-listed patents related to cabozantinib...
Exelixis
Mon, 14.10.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the companies have entered into a clinical development collaboration to evaluate the combination of Exelixis’ investigational tyrosine kinase inhibitor (TKI) zanzalintinib with Merck’s anti-PD-1 therapy KEYTRUDA® (pembrol...
Exelixis
Mon, 16.09.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced updated and final data from CABINET, a phase 3 pivotal trial evaluating cabozantinib (CABOMETYX®) versus placebo in two cohorts of patients with previously treated neuroendocrine tumors: one cohort with advanced pancreatic neuroendocrine tumors (pNET) and one cohort with advanced extra-pancreatic NET (...
Exelixis
Sun, 15.09.2024
Exelixis
US30161Q1040
Exelixis, Inc. (Nasdaq: EXEL) today announced detailed final overall survival (OS) results from CONTACT-02, a phase 3 pivotal study evaluating cabozantinib (CABOMETYX®) in combination with atezolizumab (Tecentriq®) compared with a second novel hormonal therapy (NHT) in patients with metastatic castration-resistant prostate cancer (mCRPC) and measu...
Exelixis
Information on product placements
SMART * AD
P R O D U C T S U G G E S T I O N S
